Alexion Aims To Drive PNH Diagnoses (And Soliris Sales) With Diagnostic
Executive Summary
Alexion believes the challenge of identifying new patients with the "ultra-orphan" blood disorder paroxysmal nocturnal hemoglobinuria who are candidates for the company's biologic Soliris (eculizumab) will be helped by diagnostic technology recently in-licensed by the firm
You may also be interested in...
Alexion's Soliris Could Benefit From Japan's Orphan Drug Pricing Policy
U.S.-based Alexion Pharmaceuticals has orphan designation in Japan for Soliris (eculizumab) for patients with rare paroxysmal nocturnal hemoglobinuria blood disorder.
Alexion's Soliris Could Benefit From Japan's Orphan Drug Pricing Policy
U.S. biotech firm Alexion Pharmaceuticals, which submitted a NDA in Japan for Soliris (eculizumab) for patients with rare paroxysmal nocturnal hemoglobinuria blood disorder, could benefit from the country's practice of placing a premium on innovative drugs for orphan diseases
Alexion’s Soliris Blood Treatment Will Cost Almost $400,000 Per Year
Alexion Pharmaceuticals is launching its paroxysmal nocturnal hemoglubinuria Soliris (eculizumab) with a treatment support service with case managers to help facilitate reimbursement